Literature DB >> 28555379

[Recent development of hypertension and acute renal failure in a 59-year-old woman].

M Uebner1, J Jacobi2, D Schmidt3, M Büttner-Herold4, A Mackensen5, B M Spriewald5.   

Abstract

We report on a 59-year-old woman who presented with nausea, fatigue, arterial hypertension, and acute renal failure. Clinical examination, laboratory findings of blood and urine and abdominal sonography were inconclusive. Renal biopsy revealed infiltration by a diffuse large B‑cell lymphoma. In fluorodeoxyglucose positron emission tomography/computed tomography tracer enrichment was demonstrated in both kidneys, skeletal system and retroperitoneal lymph nodes. Renal function improved already after the first cycle of R‑CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone). After chemotherapy, a complete remission, normalization of blood pressure and renal function were achieved.

Entities:  

Keywords:  Lymphoma, kidney; Lymphoma, large B‑cell, diffuse; Positron-emission tomography, fluorodeoxyglucose; Tomography, x‑ray computed

Mesh:

Substances:

Year:  2017        PMID: 28555379     DOI: 10.1007/s00108-017-0269-1

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  11 in total

1.  Primary renal lymphoma presenting with hypertension.

Authors:  Amy M Becker; Daniel C Bowers; Linda R Margraf; Jacqueline Emmons; Michel Baum
Journal:  Pediatr Blood Cancer       Date:  2007-06-15       Impact factor: 3.167

Review 2.  Unusual presentation of large B cell lymphoma: a case report and review of literature.

Authors:  L Airaghi; I Greco; M Carrabba; M Barcella; I M Baldini; P Bonara; M Goldaniga; L Baldini
Journal:  Clin Lab Haematol       Date:  2006-10

3.  Stage 2 hypertension in a child with a rapidly enlarging kidney: answer. Burkitt's lymphoma.

Authors:  Wasiu A Olowu; Kayode A Adelusola
Journal:  Pediatr Nephrol       Date:  2007-11-24       Impact factor: 3.714

4.  Sites of extranodal involvement are prognostic in patients with diffuse large B-cell lymphoma in the rituximab era: an analysis of the Surveillance, Epidemiology and End Results database.

Authors:  Jorge J Castillo; Eric S Winer; Adam J Olszewski
Journal:  Am J Hematol       Date:  2014-02-19       Impact factor: 10.047

5.  Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging.

Authors:  G Jerusalem; Y Beguin; M F Fassotte; F Najjar; P Paulus; P Rigo; G Fillet
Journal:  Blood       Date:  1999-07-15       Impact factor: 22.113

6.  Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte.

Authors:  Bertrand Coiffier; Catherine Thieblemont; Eric Van Den Neste; Gérard Lepeu; Isabelle Plantier; Sylvie Castaigne; Sophie Lefort; Gérald Marit; Margaret Macro; Catherine Sebban; Karim Belhadj; Dominique Bordessoule; Christophe Fermé; Hervé Tilly
Journal:  Blood       Date:  2010-06-14       Impact factor: 22.113

7.  Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high-risk patients with diffuse large B-cell lymphoma.

Authors:  Jeremy S Abramson; Matthew Hellmann; Jeffrey A Barnes; Peter Hammerman; Christiana Toomey; Tak Takvorian; Alona Muzikansky; Ephraim P Hochberg
Journal:  Cancer       Date:  2010-09-15       Impact factor: 6.860

8.  Malignant lymphoma of the kidney.

Authors:  Y Yasunaga; Y Hoshida; M Hashimoto; T Miki; A Okuyama; K Aozasa
Journal:  J Surg Oncol       Date:  1997-03       Impact factor: 3.454

Review 9.  The role of FDG-PET scans in patients with lymphoma.

Authors:  Pamela Seam; Malik E Juweid; Bruce D Cheson
Journal:  Blood       Date:  2007-08-20       Impact factor: 22.113

10.  Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL.

Authors:  Michael Pfreundschuh; Lorenz Trümper; Marita Kloess; Rudolf Schmits; Alfred C Feller; Christian Rudolph; Marcel Reiser; Dieter K Hossfeld; Bernd Metzner; Dirk Hasenclever; Norbert Schmitz; Bertram Glass; Christian Rübe; Markus Loeffler
Journal:  Blood       Date:  2004-02-24       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.